New approach to treatment of deadly kidney cancer
Researchers at Karolinska Institutet in Sweden have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell. When the researchers increased the mitochondrial content with an inhibitor, the cancer cells responded to the treatment. Their findings, which are published in Nature Metabolism, offer hope for more targeted cancer drugs. (Source: World Pharma News)
Source: World Pharma News - June 27, 2022 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one monovalent and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. (Source: World Pharma News)
Source: World Pharma News - June 25, 2022 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could provide an effective treatment against RSV disease, according to researchers in the Center for Translational Antiviral Research at Georgia State University. (Source: World Pharma News)
Source: World Pharma News - June 24, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK announces £1 billion R & D investment over ten years to get ahead of infectious diseases in lower-income countries
GSK plc (LSE/NYSE: GSK) announced an investment of £1bn over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries. This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR), (Source: World Pharma News)
Source: World Pharma News - June 23, 2022 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Biomarkers found that could be drug targets against a deadly form of brain cancer
Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing hope for a cancer that is highly lethal. Currently, the drug most often used to treat glioblastoma, temozolomide, is uniquely able to cross the blood/brain barrier to attack the tumor but resistance develops rapidly, and many patients do not survive for more than a year after diagnosis. (Source: World Pharma News)
Source: World Pharma News - June 22, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was completed, prompting the Centers for Disease Control and Prevention (CDC) to issue a health advisory on this so-called "COVID-19 rebound." (Source: World Pharma News)
Source: World Pharma News - June 21, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manuscripts, reinforcing the transformational benefit of Zolgensma® (onasemnogene abeparvovec) when used early. (Source: World Pharma News)
Source: World Pharma News - June 20, 2022 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novel drug combo activates natural killer cell immunity to destroy cancer cells
Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. A new study led by Penn State College of Medicine scientists finds that another type of immune cell - natural killer cells - can be harnessed to pick up the slack when T cells no longer work and may also reinvigorate T cells to attack melanoma tumors. (Source: World Pharma News)
Source: World Pharma News - June 17, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants
Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The antibodies were effective against all SARS-CoV-2 variants of concern tested and could be used alone or in an antibody cocktail to diminish the risk of infection. (Source: World Pharma News)
Source: World Pharma News - June 16, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Boehringer Ingelheim signs option to acquire Trutino Biosciences
Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences is a pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. (Source: World Pharma News)
Source: World Pharma News - June 15, 2022 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

A new technology offers treatment for HIV infection through a single injection
A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The study examined the engineering of type B white blood cells in the patient's body so as to secrete anti-HIV antibodies in response to the virus. (Source: World Pharma News)
Source: World Pharma News - June 14, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first systemic treatment for alopecia areata
Today, the U.S. Food and Drug Administration approved Olumiant (baricitinib) oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year. Today's action marks the first FDA approval of a systemic treatment (i.e. treats the entire body rather than a specific location) for alopecia areata. (Source: World Pharma News)
Source: World Pharma News - June 13, 2022 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Proteomic study of 2,002 tumors identifies 11 pan-cancer molecular subtypes across 14 types of cancer
A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowledge that greatly expands a searchable online database that has become a go-to platform for cancer data analysis by users worldwide. (Source: World Pharma News)
Source: World Pharma News - June 10, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Positive Phase 1 data from mRNA-based individualized neoantigen specific immunotherapy in patients with resected pancreatic cancer
BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). (Source: World Pharma News)
Source: World Pharma News - June 9, 2022 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Pfizer to invest $120 million to produce COVID-19 oral treatment in the U.S.
Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment will expand the production of active pharmaceutical ingredient (API) and registered starting materials (RSMs) used in the manufacture of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer's laboratories, which will create more than 250 additional high-skilled...
Source: World Pharma News - June 8, 2022 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news